Delfi Diagnostics presented interim clinical utility data for its cfDNA-based FirstLook Lung blood test in a cluster-randomized FIRSTLUNG study. The company reported that access to the assay nearly tripled overall lung cancer screening uptake and increased LDCT screening by about 1.5-fold. In the trial, Delfi said the test showed 80% sensitivity, 56% specificity, and a negative predictive value of 99.8% among nearly 3,000 patients who were behind on screening and evaluated at 28 clinics in Colorado, Florida, and North Carolina. Delfi also reported that most cancers detected through the program were stage I, a point intended to support earlier curative intervention. The company said it has submitted results to a peer-reviewed journal.